S-1: Oral fluoropyrimidine (5-FU) derivative

Phase II Trial of S-1 Plus Cisplatin in Patients with NSCLC (ASCO)
Abstract of a study presented at the 2003 ASCO annual meeting to evaluate the response and safety of combination therapy using S-1 plus cisplatin in NSCLC patients. The study concluded that S-1 plus cisplatin demonstrated a promising activity with acceptable toxicity in patients with advanced NSCLC. Further investigations of this regimen, including a controlled trial for its use as first line treatment for NSCLC, are underway. [6/03]